10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 beta--lactamase-producing Klebsiella pneumoniae epidemic clone.

      Diagnostic Microbiology and Infectious Disease
      Aged, Anti-Bacterial Agents, therapeutic use, Bacteremia, drug therapy, Colistin, Drug Synergism, Drug Therapy, Combination, Humans, Klebsiella Infections, Klebsiella pneumoniae, drug effects, enzymology, Male, Microbial Sensitivity Tests, Microbial Viability, Minocycline, analogs & derivatives, beta-Lactamases, biosynthesis

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We report the use of tigecycline, firstly with colistin and finally alone, in a patient with a persistent breakthrough bacteremia due to a Klebsiella pneumoniae isolate harboring a metallo-beta-lactamase (VIM-1) and an extended-spectrum beta-lactamase (SHV-12). Time-kill studies demonstrated that the combination of both compounds was synergistic along the first 12 h, suppressing the regrowth observed after 3 to 6 h when colistin was tested alone.

          Related collections

          Author and article information

          Comments

          Comment on this article